FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Lars Möllgård

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Physiology

Geographic Areas

Sweden

Anatomy

Co-author Network

Publications

TOP 3
Marianne B Treppendahl; Paul Cloos; Eva Hellström-Lindberg; Lars Möllgård; Kirsten Grønbaek
Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q.
Gunnar Juliusson; Holger Karbach; Karin Karlsson; Vladimir Lazarevic; Sören Lehmann; Lars Möllgård; Dick Stockelberg; Anders Wahlin; Petar Antunovic; Mats Brune; Asa Derolf; Hans Hägglund; Helene Hallböök; Martin Höglund
Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.
Lars Möllgård; Lars Nilsson; Jan Maxwell Nørgaard; Anna Porwit; Leonie Saft; Marianne Bach Treppendahl; Hanne Vestergaard; Eva Hellström-Lindberg; Jan Astermark; Inge Høgh Dufva; Ingunn Dybedal; Elisabeth Ejerblad; Hege Garelius; Kirsten Grønbæk; Martin Jädersten; Monika Jansson; Lars Kjeldsen; Olle Linder; Eva Hellström Lindberg
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Lars Möllgård (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Marianne B Treppendahl; Paul Cloos; Eva Hellström-Lindberg; Lars Möllgård; Kirsten Grønbaek
Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q.
European journal of haematology 2013;90(3):259-60.
2011: Gunnar Juliusson; Holger Karbach; Karin Karlsson; Vladimir Lazarevic; Sören Lehmann; Lars Möllgård; Dick Stockelberg; Anders Wahlin; Petar Antunovic; Mats Brune; Asa Derolf; Hans Hägglund; Helene Hallböök; Martin Höglund
Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.
Cancer 2011;117(18):4238-46.
2011: Lars Möllgård; Lars Nilsson; Jan Maxwell Nørgaard; Anna Porwit; Leonie Saft; Marianne Bach Treppendahl; Hanne Vestergaard; Eva Hellström-Lindberg; Jan Astermark; Inge Høgh Dufva; Ingunn Dybedal; Elisabeth Ejerblad; Hege Garelius; Kirsten Grønbæk; Martin Jädersten; Monika Jansson; Lars Kjeldsen; Olle Linder; Eva Hellström Lindberg
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
Haematologica 2011;96(7):963-71.
2011: S Lehmann; Lars Möllgård; A Ravn; Dick Stockelberg; Ulf Tidefelt; A Wahlin; Lovisa Wennström; A Rangert Derolf; P Antunovic; L Carlsson; S Deneberg; M Höglund; Gunnar Juliusson
Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.
Leukemia 2011;25(7):1128-34.
2009: Gunnar Juliusson; Petar Antunovic; Asa Derolf; Sören Lehmann; Lars Möllgård; Dick Stockelberg; Ulf Tidefelt; Anders Wahlin; Mattias Höglund
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.
Blood 2009;113(18):4179-87.
2008: Lars Möllgård; Stefan Deneberg; Hareth Nahi; Sofia Bengtzen; Kerstin Jonsson-Videsäter; Thoas Fioretos; Anna Andersson; Christer Paul; Sören Lehmann
The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.
Cancer chemotherapy and pharmacology 2008;62(3):439-48.
2008: Hareth Nahi; Galina Selivanova; S Lehmann; Lars Möllgård; S Bengtzen; H Concha; A Svensson; Klas G Wiman; Mats Merup; Christer Paul
Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
British journal of haematology 2008;141(4):445-53.
2008: Hareth Nahi; Sören Lehmann; Sofia Bengtzen; Monika Jansson; Lars Möllgård; Christer Paul; Mats Merup
Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia.
Leukemia & lymphoma 2008;49(3):508-16.
2007: Christina Löfgren; Sören Lehmann; Kerstin Jönsson-Videsäter; Lars Möllgård; Olle Linder; Ulf Tidefelt; Moustapha Hassan; Christer Paul
Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
Therapeutic drug monitoring 2007;29(5):626-31.
2005: Parvaneh Afsharian; Lars Möllgård; Zuzana Hassan; Hanjing Xie; Eva Kimby; Moustapha Hassan
The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma.
European journal of haematology 2005;75(3):206-11.
2003: Gunnar Juliusson; Mattias Höglund; Karin Karlsson; Christina Löfgren; Lars Möllgård; Christer Paul; Ulf Tidefelt; Magnus Björkholm
Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study.
British journal of haematology 2003;123(5):810-8.
2003: Lars Möllgård; Malin Prenkert; Adam Smolowicz; Christer Paul; Ulf Tidefelt
In vitro chemosensitivity testing of selected myeloid cells in acute myeloid leukemia.
Leukemia & lymphoma 2003;44(5):783-9.
2002: Jeanette Lundin; Eva Kimby; Magnus Björkholm; Per-Anders Broliden; Fredrik Celsing; Viktoria Hjalmar; Lars Möllgård; Peppy Rebello; Geoff Hale; Herman Waldmann; Håkan Mellstedt; Anders Osterborg
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
Blood 2002;100(3):768-73.
2001: Bertil Uggla; Lars Möllgård; Elisabeth Ståhl; L L Mossberg; Mats G Karlsson; Christer Paul; Ulf Tidefelt
Expression of topoisomerase IIalpha in the G0/G1 cell cycle phase of fresh leukemic cells.
Leukemia research 2001;25(11):961-6.
2001: Lars Möllgård; E Hellberg; Adam Smolowicz; Christer Paul; Ulf Tidefelt
Interactions between P-glycoprotein and drugs used in the supportive care of acute myeloid leukemia patients.
Leukemia & lymphoma 2001;42(1-2):177-85.
2000: Lars Möllgård; Ulf Tidefelt; B Sundman-Engberg; Christina Löfgren; Christer Paul
In vitro chemosensitivity testing in acute non lymphocytic leukemia using the bioluminescence ATP assay.
Leukemia research 2000;24(5):445-52.
2000: Ulf Tidefelt; Jan Liliemark; Astrid Gruber; Eva Liliemark; B Sundman-Engberg; Gunnar Juliusson; Leif Stenke; A Elmhorn-Rosenborg; Lars Möllgård; S Lehman; Dawei Xu; A Covelli; B Gustavsson; Christer Paul
P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(9):1837-44.
1998: Lars Möllgård; Ulf Tidefelt; B Sundman-Engberg; Christina Löfgren; S Lehman; Christer Paul
High single dose of mitoxantrone and cytarabine in acute non-lymphocytic leukemia: a pharmacokinetic and clinical study.
Therapeutic drug monitoring 1998;20(6):640-5.